Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
- I Tried Strava’s New Strength Coach Feature, and I’m Optimistic
- 6 Questions to Ask Before Hiring a Speaker For Your Next Event
- Vaden Consultancy – Company Profile
- Donald Trump Is Learning That He Can’t Steal This Election
- 13 Shocking Historical Sex Laws I Can’t Believe Were Real
- What it is and how it works
- No agenda, no rush, no leaving San Francisco: Benchmark’s partners on investing in a frenzied market
- Will Disneyland Move the Matterhorn for Tomorrowland’s Reimagining? Why We’re Skeptical of Rumors
Browsing: real estate
The stock market is enjoying its best week of 2023, but some names may have gotten ahead of themselves. …
A few banks raised their yields on CDs, even as the Federal Reserve stood pat on rates for a second consecutive time. …
These stocks can benefit from a convergence of key factors, Piper Sandler says …
Analysts aren't ready to take their foot off the pedal on Apple — even after the dominant smartphone player warned of softer demand in the current…
High-dividend stocks can be a good way to earn income in the face of market volatility, but not all dividends are necessarily safe. …
Profit takers pushed the stock lower 3% in extended trading after Apple signaled the company may not return to growth in the holiday quarter. …
These stocks can benefit from a decline in Treasury yields, according to Jefferies. …
Here are the biggest calls on Wall Street on …
A chunk of the Wall Street chatter Friday morning centered around Apple and its latest quarterly report. …
Longtime investor Bill Gross said Thursday that regional banks are poised to bounce back with the tailwind of falling interest rates. …
Pros on CNBC discussed Starbucks after the company reported fiscal Q4 earnings that beat on both earnings and revenue. …
Steve Eisman of the "The Big Short" fame said Thursday that one mantra he swears by is telling him that buying beaten-up bank stocks won't be…
In the view of one bond market whale, "T-bill and chill" is officially on its way out. …
This biotech's "blockbuster drug" targeting dermatology and rheumatology could achieve $4.2 billion in U.S. revenue, according to Stifel. …